𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus

✍ Scribed by Hiroyuki Sekiguchi; Seiji Akiyama; Michitaka Fujiwara; Hajime Nakamura; Ken Kondo; Yasushi Kasai; Katsuki Ito; Junichi Sakamoto; Hiroshi Takagi

Book ID
112759769
Publisher
Springer
Year
1999
Tongue
English
Weight
76 KB
Volume
29
Category
Article
ISSN
1436-2813

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of dose-dense paclitaxel,
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck
✍ Ricardo Hitt; Antonio Jimeno; Jose MarΓ­a MillΓ‘n; Daniel Castellano; HernΓ‘n CortΓ© πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 4 views

## Abstract ## BACKGROUND The current study evaluated the feasibility and clinical activity of a combination of paclitaxel, cisplatin, 5‐fluorouracil (5‐FU), and leucovorin administered on a biweekly schedule to patients with recurrent or unresectable squamous cell carcinoma of the head and neck (

Neoadjuvant chemotherapy with cisplatinu
Neoadjuvant chemotherapy with cisplatinum/5-fluorouracil/low-dose leucovorin for advanced squamous cell carcinoma of the esophagus
✍ Hiroko Ide; Tsutomu Nakamura; Kazuhiko Hayashi; Reiki Eguchi; Keiji Tanigawa; Ma πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 48 KB πŸ‘ 1 views

Forty-four patients with advanced esophageal squamous cell carcinoma were treated with biochemical modulated combination chemotherapy and surgery. Treatment consisted of cisplatinum (70 mg/m 2 /day 1, day 22), 5-fluorouracil (5-FU; 700 mg/m 2 /day, days 1-5, 22-26), and leucovorin (20 mg/m 2 /day, d